Identifiants & Marche
Ticker
RUBY
ISIN
US78116T1034
CIK
0001709401
Bourse
NASDAQ
Devise
USD
Entreprise
Pays
US
Siege
N/A
Fondee
N/A
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.